Start with indication and regulatory status
Projects described as cell or gene therapy may be in very different stages: some are approved for specific indications, while others remain in clinical trials or research.
FDA, ClinicalTrials.gov, academic medical centers and authoritative scientific sources are better starting points than promotional claims.
Cross-border research needs clear boundaries
When researching across borders, confirm whether a program targets a specific disease, has defined eligibility, is research-stage, and explains risks and costs.
This content is for public-information reference only and is not treatment advice or a recommendation.